Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital Schleswig Holstein, Campus Lübeck, in Germany.
A real-world analysis of avelumab and axitinib to treat advanced renal cell carcinoma supports the frontline use of the combination and confirmed the findings of JAVELIN Renal 101 (NCT02684006), said Axel Merseburger, MD, professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.
Merseburger presented these findings at the American Society of Clinical Oncology Genitourinary Cancers Symposium, held February 13-15, 2025, in San Francisco, California.
This transcript has been edited for clarity; captions were auto-generated.
Transcript
What was the rational for conducting the AVION study, a real-world analysis of avelumab and axitinib for renal cell carcinoma?
The rationale and the idea was we have the approval in a lot of countries for avelumab and axitinib for treating advanced and metastatic renal cell carcinoma, and we wanted to have a look at if this trial data, which was published and shown at several conferences, would stand also in real-world data in countries like Russia, Greece, and Germany that were the countries included in the AVION trial.
Were there any notable differences in outcomes or adverse events between the real-world study and what was seen in JAVELIN Renal 101?
Now, fortunately not, and this was really real life in European and even Russian sites that recruited the patients. Some of them haven't had any access to further subsequent treatment, which probably resulted also in this overall survival, similar to JAVELIN Renal 101.1
I think no, there's not a big difference, and the real-world data supports what we have found in the pivotal trial.
The observation period was 24 months. Is there a need for a longer follow-up period and what might it tell us or confirm?
Yes, we will do the follow-up. We will continue to do the follow-up and hope to report maybe at next year's ASCO GU 2026. Also, the publication plan is there. And once we have had more follow-up data, it's going to be published in a journal. We don't know where yet, but it's going to be definitely published.
Reference
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047
Nerandomilast Slows Lung Function Decline in Patients With IPF
May 19th 2025The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More